Tuesday, May 22, 2018 Daily Archives

Novasep Invests in Belgian Fill & Finish Site; Cites Lack of Global Capacity

by

The tension on the market surrounding the lack of fill & finish capabilities is ‘visible,’ says Novasep as it pumps US$12 million into a site in Belgium. The investment at Novasep’s site in Seneffe, Belgium will support the fill & finish for viral vectors, mAbs and other low-volume biologics. According to Laure Saloin, a spokesperson from the French life sciences services firm, the €10 million (US$11.8 million) spend supports the “one-stop-shop approach for our monoclonal antibodies and our viral-vectors bulk…

May 22, 2018

Biogen Paying $650m to Up Stake in Samsung Bioepis

by

Biogen has opted to increase its control in biosimilar venture Samsung Bioepis to 49.5%, according to partner Samsung BioLogics. Biogen sent South Korean biomanufacturer Samsung BioLogics a letter last week declaring its intention to increase its stake in the firms’ joint venture Samsung Bioepis from 5.4% to 49.5%. According to Samsung BioLogics, Biogen will pay around 700 billion Won (US$650 million) for an additional 44.6% stake in the JV, with the deal expected to take two to three months to…

May 22, 2018